Au@Prussian Blue Hybrid Nanomaterial Synergy with a Chemotherapeutic Drug for Tumor Diagnosis and Chemodynamic Therapy

ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39493-39502. doi: 10.1021/acsami.9b13470. Epub 2019 Oct 15.

Abstract

Recently, the chemodynamic therapy (CDT) has been widely reported and applied to tumor therapy. However, only low level hydroxyl radicals (•OH) generated by the endogenous hydrogen peroxide alone are insufficient to kill the cancer cells. To overcome the insufficient therapeutic effect, this study reports a novel CDT based on Fenton catalyst Au@Prussian blue nanocubes (Au@PB NCs), subsequently encapsulated with doxorubicin (Dox). The in vitro and in vivo results indicate that the Dox-Au@PB NCs can take synergistic effects on tumor suppressor by CDT. In addition, Au@PB NCs possess high X-ray computed tomography contrast enhanced efficiency about ∼27.13 HU·mL·mg-1. This study highlights a great potential of the Dox-Au@PB NCs for tumor diagnosis and CDT.

Keywords: Fenton reaction; chemo-dynamic therapy; computed tomography imaging; doxorubicin; hydrogen peroxide; hydroxyl radicals.

MeSH terms

  • Animals
  • Cell Line
  • Cell Line, Tumor
  • Contrast Media* / chemistry
  • Contrast Media* / pharmacology
  • Doxorubicin* / chemistry
  • Doxorubicin* / pharmacology
  • Drug Carriers* / chemistry
  • Drug Carriers* / pharmacology
  • Ferrocyanides* / chemistry
  • Ferrocyanides* / pharmacology
  • Gold* / chemistry
  • Gold* / pharmacology
  • Mice
  • Nanostructures* / chemistry
  • Nanostructures* / therapeutic use
  • Neoplasms, Experimental* / diagnostic imaging
  • Neoplasms, Experimental* / drug therapy
  • Tomography, X-Ray Computed*

Substances

  • Contrast Media
  • Drug Carriers
  • Ferrocyanides
  • Gold
  • Doxorubicin
  • ferric ferrocyanide